These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8010 related articles for article (PubMed ID: 11881530)

  • 1. G 3139. Augmerosen, Bcl-2 antisense oligonucleotide--Genta, GC 3139, Genasense.
    Drugs R D; 2002; 3(1):44-9. PubMed ID: 11881530
    [No Abstract]   [Full Text] [Related]  

  • 2. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genasense (Genta Inc).
    Banerjee D
    Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Bcl-2 antisense therapy for lymphomas.
    Cotter FE; Waters J; Cunningham D
    Biochim Biophys Acta; 1999 Dec; 1489(1):97-106. PubMed ID: 10807000
    [No Abstract]   [Full Text] [Related]  

  • 5. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.
    Moreira JN; Santos A; Simões S
    Rev Recent Clin Trials; 2006 Sep; 1(3):217-35. PubMed ID: 18473975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
    Klasa RJ
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):25-31. PubMed ID: 15651174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism.
    Stein CA
    J Natl Cancer Inst; 1996 Apr; 88(7):391-3. PubMed ID: 8618230
    [No Abstract]   [Full Text] [Related]  

  • 9. [Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results].
    Büchele T
    Onkologie; 2003 Dec; 26 Suppl 7():60-9. PubMed ID: 14716145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
    Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA
    Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854
    [No Abstract]   [Full Text] [Related]  

  • 12. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
    Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
    Ramanarayanan J; Hernandez-Ilizaliturri FJ; Chanan-Khan A; Czuczman MS
    Br J Haematol; 2004 Dec; 127(5):519-30. PubMed ID: 15566355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
    Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
    Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genta initiates trials with Genasense.
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):6. PubMed ID: 12113068
    [No Abstract]   [Full Text] [Related]  

  • 18. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
    Stewart A
    Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683
    [No Abstract]   [Full Text] [Related]  

  • 20. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 401.